



SUPPLEMENTARY FIG. S3. Dose response assessment of CLP290 pharmacodynamics after traumatic brain injury (TBI). (A) The prodrug CLP290 was administered to assess the therapeutic potential in preserving KCC2 within perilesioned somatosensory cortex after controlled cortical impact (CCI). CLP290 pharmacodynamics in the rat after modeled TBI were assessed for the minimum effective dose to provide improved functional recovery by four days after CCI using the (B) whisker adhesive removal and (C) Rotarod tasks to test somatosensory integration deficits. * $p < 0.05$ relative to TBI/Veh (0 mg/kg).